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Entactin: A possible auto-antigen in the pathogenesis of non-Goodpas-
ture anti-GBM nephritis. It has recently been demonstrated that many
patients with various types of glomerulonephritis have antibodies to the
6M guanidine-HCI extract of glomerular basement membrane (Bygren
et al, Nephrol Dial Transplant 4:254—261, 1989). In the present study a
150 K protein was isolated from the guanidine extract of bovine
glomerular basement membrane utilizing ion exchange and gel filtration
chromatographic procedures. Amino acid analysis and size of the
isolated protein revealed similarity to that of entactin/nidogen. The
identity of this protein as entactin/nidogen was further suggested by its
precipitation with two different antibodies in a radioimmunoassay and
by its reaction with four different antibodies in a sandwich ELISA.
Inhibition of the antibodies to 150 K by bovine entactin, which was
isolated separately and sequenced for amino acids, confirmed the
identity of the 150 K protein as entactinlnidogen. Furthermore, it was
shown that about one third of those patients who show antibodies to the
crude guanidine extract have circulating antibodies directed against
entactin. This was further confirmed by the competitive inhibition of
antibodies to the crude guanidine extract in one of the positive serum by
entactin in an ELISA inhibition and by immunoblotting experiments.
These observations propose entactin as a possible non-Goodpasture
glomerular basement membrane antigen that could be involved in the
pathogenesis of certain forms of autoimmune glomerulonephritis (non-
Goodpasture anti-GBM glomerulonephritis) in man. Most of these
patients have a granular pattern of the immunoglobulin deposition along
the glomerular basement membrane. This suggests the possibility that
anti-GBM glomerulonephritis in human beings can have non-linear
immunoglobulin deposits along the GBM.
Glomerular basement membrane (GBM) is involved in a
variety of primary and secondary glomerulonephritides which
constitute an important group of renal diseases in humans. It is
now well established that a majority of glomerulonephritis
diseases have immunological origin [1—3]. The two major im-
munologic mechanisms causing glomerular injury are immune
complex disease and anti-GBM disease [4]. Although constitut-
ing only a minority of the glomerular diseases, anti-GBM
nephritis is an important clinical entity. Most of these patients
have severe progressive renal disease with an extremely high
mortality if left untreated [5—7].The only well known prototype
of anti-GBM nephritis is Goodpasture's syndrome consisting of
nephritis, with or without pulmonary hemorrhage, and linear
deposit of IgG on GBM as seen by direct immunofluorescence
[8]. The antigen involved in Goodpasture's syndrome is located
on the M2 peptide which is the non-collagenous globular
domain (NC1) of the a3 chain of collagen IV [9—121. A few
earlier studies have hinted a possible role of other GBM
antigens (non-Goodpasture GBM antigens) in the pathogenesis
of glomerulonephritis in humans [7, 13, 14]. They suggested that
anti-GBM antibodies occur more frequently than is generally
thought and may play a role in many more types of glomerulo-
nephritis than in only the well defined form of anti-GBM
nephritis. Kefalides and coworkers [15] reported the presence
of anti-laminin and anti-collagen IV antibodies in patients with
post-streptococcal glomerulonephritis. Recently, it has been
shown that circulating IgA antibodies in complexes with fi-
bronectin bind to the collagen IV in IgA nephropathy [16].
Nevertheless, the involvement of autoantibodies to glomerular
antigens, other than the Goodpasture antigen, in the pathogen-
esis of autoimmune nephritis in humans still remains unclear.
On the other hand, several glomerular antigens have been
described in experimental glomerulonephritis in animals; such
as 330 K and 90 K glycoproteins (gp330 and gp9O) in Heymann
nephritis [17—211, laminin and collagen IV in mercuric chloride-
induced nephritis in rats [22] and laminin in a murine model of
graft versus host (GvH) disease [23]. Furthermore, a study
conducted at our hospital has shown that more than 40% of the
patients admitted to our clinic for investigation of glomerulone-
phritis have serum IgG, 1gM and/or IgA reacting with the
antigens present in the crude 6 M guanidine-HCI extract of
GBM [24]. These observations strengthen our belief in the
possible role of non-Goodpasture anti-GBM antibodies in the
pathogenesis of several forms of glomerulonephritis in humans.
In the present study we have identified entactin/nidogen (entac-
tin [25] and nidogen [26] were isolated as two separate but
related ubiquitous components of basement membranes; but
recent amino acid sequence analysis and cloning has shown that
the two proteins are identical [27, 28]), a suiphated glycoprotein
component of GBM with a molecular weight of 150,000, as a
possible auto-antigen reacting with several sera from patients
with various types of glomerulonephritis.
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Preparation of a 150 K protein from GBM
Preparation of GBM. Bovine GBM was prepared as de-
scribed earlier. The glomeruli were isolated from bovine kid-
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neys by sieving procedures as described elsewhere [29] in
presence of the following protease inhibitors to inhibit endoge-
nous proteolysis: 4 m N-ethyl-maleimide, 1 m phenylmeth-
ylsulphonyl fluoride, 5 mr'i benzamidine-HCI, 25 m 6-amino-
hexanoic acid and 10 mM EDTA. Isolated glomeruli were
sonicated to remove the cellular debris.
Guanidine extraction of GBM. GBM was briefly homoge-
nized in ten volumes of 6 M guanidine hydrochloride, 0.05 M
Tris-HC1, pH 7.5, containing protease inhibitors as above. The
extraction was performed overnight at 37°C with continuous
stirring. The extract was clarified by centrifugation at 100,000 x
g for 60 minutes, and the extraction procedure was repeated
again with the pellets. The two extracts were then pooled.
Chromatographic procedures. One hundred and fifty millili-
ters of the guanidine extract was dialyzed against three changes
of 10 volumes of 6 M urea, 0.05 M Tris-HCI, pH 8.4, containing
protease inhibitors: 2.5 mM EDTA, 0.5 m N-ethyl maleimide
and 0.5 mri phenylmethylsulphonyl fluoride and passed over a
DEAE Sephacel column (Pharmacia, Uppsala, Sweden) equil-
ibrated with the same buffer. The bound proteins were eluted by
a linear salt gradient (0 to 0.75 M NaCI) and the fractions were
analyzed by SDS-PAGE on 6 to 25% gradient polyacrylamide
slab gels [30] and by ELISA as described below. Fractions
containing 150 K proteins were concentrated to 15 ml by a
YM1O filter (Amicon, Danvers, Massachusetts, USA) and ap-
plied to a Sephacryl S-300 gel filtration column (Pharmacia)
equilibrated with 6 M guanidine-HCI, 0.05 M Tris-HCI, pH 7.5.
The fractions were analyzed, as above, by ELISA and SDS-
PAGE after precipitation with 10 volumes of 95% ethanol. The
fractions containing 150 K proteins were pooled and concen-
trated to 2 ml, dialyzed against three changes of 6 M urea, 0.02
M sodium acetate, pH 4.8 containing protease inhibitors, and
injected to a Mono S FPLC column (Pharmacia) equilibrated
with the same buffer. The bound proteins were eluted by a
linear salt gradient (0 to 1 M NaCl) and fractions analyzed by
SDS-PAGE and ELISA. The fractions containing 150 K pro-
teins were rechromatographed, if necessary, on a Sephacryl
S-300 column.
Immunological methods. Fractions after each chromato-
graphic step were analyzed by ELISA [311 as follows: Each
fraction was coated to one well of a microtiter plate (NUNC;
Roskilde, Denmark) in a dilution of 1 in 20 in 0.05 M sodium
carbonate, pH 9.5, and incubated overnight at room tempera-
ture. The plates were washed three times with 0.15 M NaCI,
0.05% Tween 20 and rabbit antiserum raised against the 150 K
protein from bovine GBM, diluted I in 1000 in PBS-BSA (0.05
M phosphate, 0.15 M NaC1, 0.05% Na azide, pH 7.4, 0.05%
Tween 20, 2 mg BSAImI) added to each well. Mter incubating
for one hour the plates were again washed and anti-rabbit
IgG-alkaline phosphatase conjugate (Orion diagnostics, Esbo,
Finland), diluted 1 in 1000 in PBS-BSA added. The plates were
again incubated for one hour at room temperature, washed and
substrate, p-nitrophenyl phosphate (Sigma Chemical Co., St.
Louis, USA), 1 mg/ml in 1 M diethanolamine, pH 9.8; 200 j.d in
each well, added. The absorbance was read in a Multiscan (Flow
Laboratories, Lugano, Switzerland) microtiter plate reader.
Identification of the 150 K protein as entactin/nidogen
The isolated 150 K protein was radioiodinated with 1251 by the
lactoperoxidase method [32]. Fifty microliters of this radiola-
beled 150 K protein (containing approximately 5000 cpm) was
mixed with 50 sl of two different antibodies [anti-150K and
anti-nidogen (from Dr. Rupert Timpl, Max Planck Institute,
Munich, FRG) antibodies] in a serial dilution of PBS-BSA. Fifty
microliters of second antibody (anti-rabbit IgG) was then added
and RIA performed using standard procedures.
Furthermore, entactin was independently isolated from bo-
vine GBM using slightly different procedures from those de-
scribed above [33]. Briefly, entactin was extracted from base-
ment membranes with 6 M guanidine, 50 m phosphate, pH 7.4
containing protease inhibitors listed above. The extracts were
equilibrated by dialysis into 6 M urea, 50 m phosphate, pH 7.4
and applied to a DEAE sephacel column in the same buffer, and
then eluted in a NaCI gradient. Entactin was then applied to a
column of S-Sepharose (Pharmacia) in 6 M urea, 20 m sodium
acetate, pH 4.8, and eluted in a NaC1 gradient. Entactin
containing fractions were further purified by Sephacryl S-300
gel filtration in 6 M guanidine, 50 mti phosphate, pH 7.4. Final
purification was achieved by chromatography on a Mono Q
column (Pharmacia) in 6 M urea, 50 mM Tris, pH 7.4. Entactin
was eluted in a NaCI gradient. The identity of the protein as
entactin was confirmed by amino acid sequence determination
on a thrombin peptide [33]. Two different mouse monoclonal
antibodies (a and a') and rabbit polyclonal antibodies against
entactin were raised. The purified 150 K protein was then
coated to microtiter plates and ELISA performed as described
above using four different first antibodies: rabbit anti-iSO K
polyclonal, rabbit anti-entactin polyclonat, and mouse anti-
entactin monoclonal a and a' antibodies.
Next, an inhibition ELISA was performed as follows: Serial
dilutions of entactin and Goodpasture antigens were mixed
overnight with a representative serum (serum from a patient
with glomerulonephritis having antibodies to 150 K protein)
diluted 1 in 20, transferred to an ELISA plate coated with the
150 K protein, and ELISA performed as described above.
Analysis of anti-entactin antibodies in patient sera
Sera. Sera from 89 patients with renal diseases who were
previously shown to possess IgG/IgM/IgA antibodies to the
crude 6 M guanidine-HCI extract of GBM [24] were randomly
selected for the present study. These included patients with
primary glomerulonephritides like proliferative glomerulone-
phritis, IgA nephropathy, membranous nephropathy, extra-
capillary glomerulonephritis, mesangio-capillary glomerulone-
phritis as well as glomerulonephritides secondary mainly to
systemic vasculitides and collagen vascular diseases. Further-
more sera from 18 patients with Goodpasture's syndrome and
45 sera obtained from healthy blood donors were also analyzed
for anti-entactin antibodies.
Antigens and anti-sera.
i) The following antigens were used for this study:
a) 150 K as obtained in intact form after various chromato-
graphic steps described above
b) Bovine entactin
c) Gal al-3Gal-HSA (BioCarb AB, Lund, Sweden).
d) Crude 6 M guanidine-HCI extract of bovine GBM
ii) Rabbit anti-iSO K antiserum was used as a reference serum.
Immunological methods. a) ELISA. Antibodies to entactin in
sera from various patients, normal sera and the reference serum
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were tested by sandwich ELISA as follows: Microtiter plates
were coated with 150 K (145 nglml in 0.05 M sodium carbonate,
pH 9.5; 200 d in each well) and incubated overnight at room
temperature. Sera (200 d) diluted 1 in 20 in PBS-BSA were
added to each well and incubated for one hour at room
temperature. The plates were washed three times with 0.9%
NaC1, 0.05% Tween 20 and the conjugate (200 td), anti-human
IgG/IgM/IgA-alkaline phosphatase and anti-rabbit IgG-alkaline
phosphatase (for the reference serum), diluted 1 in 1000 in
PBS-BSA. The plates were incubated for one hour, again
washed and the substrate, p-nitrophenyl phosphate (1 mg/mI in
1 M diethanolamine, pH 9.8) added. The absorbance was read at
zero time and after 30 minutes in a multiscan microtiter plate
reader. Next, the sera in various dilutions were run using the
same protocol.
Next, all sera were analyzed under similar conditions using
bovine entactin as the coat (150 ng/ml).
Furthermore, IgG subclasses were determined for those sera
which were positive for IgG anti-entactin antibodies by the
following procedure:
Microtiter plates were coated with 150 K and sera incubated
as described above. Next, mouse anti-human IgG1/IgG2/IgG3/
IgG4 monoclonal antibodies (Unipath, Birmingham, UK) di-
luted 1 in 1000 in PBS-BSA were added and plates incubated for
one hour. In the next step rabbit anti-mouse-alkaline phos-
phatase conjugate (Dakopatts, Copenhagen, Denmark) in 1 in
1000 dilution was added and ELISA performed as described
above.
The same protocol, as described for analyzing anti-entactin
antibodies, was applied for the analysis of antibodies against the
crude guanidine extract and Gal al-3 Gal, except that microtiter
plates were coated with crude guanidine extract of bovine GBM
(5 g/ml) and Gal al-3 Gal-HSA (1 pg/m1), respectively.
For ELISA inhibition, a fixed dilution of an anti-entactin
positive serum (1 in 20) was mixed overnight with serial
dilutions of entactin (150 pg/ml undiluted), 6 M guanidine-HCI
extract of GBM (5 mg/mi undiluted) and NC1 (200 sg/ml
undiluted), respectively, and transferred to a microtiter plate
coated with crude 6 M guanidine-HCI extract of bovine GBM
the next day and ELISA performed as described above.
In order to show that the antibodies to entactin detected in
various sera were not the antibodies against Gal al-3 Gal, a
study utilizing inhibition ELISA was performed. Two sera, one
positive for both anti-entactin and anti-Gal crl-3 Gal antibodies
and the other positive only for anti-Gal al-3 Gal antibodies,
were selected. A fixed dilution of these sera (1 in 20) were
mixed with serial dilutions of entactin (150 pg!ml undiluted) and
Gal al-3Gal-HSA (1 mg/mI undiluted) and allowed to equili-
brate overnight at room temperature. The next day they were
transferred to the microtiter plates already coated with entactin
and Gal al-3Gal-HSA and the ELISA was repeated as de-
scribed above.
b) Immunoblotting studies. Western blots were performed
according to Burnett [34]. Crude guanidine extract of bovine
GBM and the 150 K protein were electrophoresed on a poly-
acrylamide slab gel (Phast 4-15%gradient gel, Pharmacia), and
the proteins were transferred to nitrocellulose papers using
PhastTransfer semi-dry electrophoretic transfer unit (Pharma-
cia). Mter blocking the unbound sites with 5% PBS-BSA the
nitrocellulose papers were incubated for two hours with the
following sera: one serum containing anti-iSO K antibodies
(serum 1), one negative serum (serum 2) and the reference
serum. All sera were diluted 1 in 20 in 0.1% PBS-BSA.
Additionally, one set of nitrocellulose papers were incubated
with the serum 1 already mixed with the 150 K protein (7.5
g/ml). The papers were then washed three times with 0.1%
PBS-BSA and incubated with the conjugates [Goat anti-human
IgG colloid gold and goat anti-rabbit IgG-colloid gold (Auro-
Probe BLplus, Janssen Biotech, Olen, Belgium)] diluted 1 in
100 in 0.1% PBS-BSA for two hours, followed by silver
enhancement for 15 minutes using intenSE BL silver enhance-
ment system (Janssen Biotech).
Results
Our previous study has demonstrated that approximately
40% of the patients with various types of glomerulonephritis
that come to the nephrology clinic for investigations show
antibodies to the crude 6 M guanidine-HCI extract of GBM [24].
As this crude extract contains a number of glycoproteins, it was
interesting to find out which one of these glycoproteins is
identified by the antibodies in the sera of those patients. Hence,
we performed immunoblotting experiments, where the crude
extract was electrophoresed, transferred to nitrocellulose
sheets and immunostained with several positive sera. mci-
dently, several of these sera stained the protein bands in the
region of 150 K. This led us to purify the glycoproteins in this
region from the guanidine extract of GBM.
Isolation of the 150 K protein from the guanidine extract of
GBM
Bovine GBM was extracted with 6 M guanidine HC1, 0.05 M
Tris-HCI, pH 7.5 in presence of protease inhibitors to minimize
endogenous proteolysis. The extract was initially passed over
DEAE Sephadex column equilibrated with 6 M urea, 0.05 M
Tris-HCI, pH 8.4. All of this protein bound to the column and
could be eluted early, as a broad peak between 0.05 and 0.20 M
NaCl (Figs. 1 and 2) as determined by ELISA and SDS-PAGE.
Chromatography on a Sephacryl S-300 column of the fractions
containing this protein resulted in separation of its various
peptides (Figs. 1 and 2). The protein was further purified by
chromatography on a Mono-S FPLC column equilibrated with 6
M urea, 0.02 M sodium acetate, pH 4.8. All of it bound to the
column and could be eluted as a sharp peak at 0.22 to 0.28 M
NaC1 (Figs. 1 and 2). Final purification of this protein was
achieved by rechromatography on a Sephacryl S-300 column.
The protein thus obtained was approximately 95% pure elec-
trophoretically.
Specificity of the antibodies to the crude guanidine extract of
GBM
To study the specificity of the antibodies to the crude
guanidine extract of GBM a study of ELISA inhibition was
performed. Crude guanidine extract was coated to microtiter
plates and a representative serum (serum that had previously
shown antibodies to the 150 K protein), mixed with serial
dilutions of 150 K protein were added and ELISA performed.
The activity of the antibodies to the crude extract was well
blocked by the 150 K protein (Fig. 3). Furthermore, in an
immunoblotting experiment crude guanidine extract of bovine
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Fig. 1. Chromatographic steps involved in isolation of 150 K protein
from 6 M guanidine-HC1 extract of bovine GBM. The sample was
dialyzed against 6 M urea, 0.05 M Tris-HCI, pH 8.4, containing protease
inhibitors and applied to a DEAE cellulose column equilibrated with the
same buffer (A). The bound proteins were eluted with a linear salt
gradient (0 to 0.75 M NaCI). P1 denotes the pool containing the 150 K
protein which was used for further purification. This pool was concen-
trated and applied to a Sephacryl S-300 column equilibrated with 6 M
guanidine-HCI, 0.05 M Tris-HCI, pH 7.5 containing protease inhibitors
(B). P2 indicates the pool containing the 150 K protein. The void (V0)
and the total (V1) volumes of the column are marked by the arrows. The
pool P2 from the S-300 chromatography was concentrated and dialyzed
against 6 M urea, 0.02 M Na acetate, pH 4.8 containing protease
inhibitors and applied to a Mono-S FPLC column equilibrated with the
same buffer (C). The bound proteins were eluted using a linear salt
gradient (0 to 1 M NaCI). P3 indicates the pool containing the 150 K
protein.
Fig. 2. SDS-PAGE of the pools containing 150 K protein. The fractions
after each chromatographic step were subjected to electrophoresis on a
polyacrylamide gradient (6 to 25%) slab gel and stained with Coomasie
Brilliant blue. All samples were reduced with 1% mercaptoethanol prior
to electrophoresis. Lane I: Starting material (6 M guanidine-HCI extract
of bovine GBM), lane 2: Pool P1 after DEAE chromatography, lane 3:
Pool P2 after S-300 gel filtration, lane 4: Pool P3 after Mono-S FPLC,
lane 5: purified 150 K protein after rechromatography of pool P3 on
Sephacryl S-300 column.
0.0
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Fig. 3. Specificity of the antibodies to the crude guanidine extract of
GBM. Crude guanidine extract of bovine GBM was coated to a
microtiter plate and one representative serum (serum that had previ-
ously shown antibodies to the 150 K protein), mixed with serial
dilutions of the 150 K protein (•, 150 sg/ml undiluted), crude guanidine
extract (EJ mg/mi undiluted) and NC! (0, 200 ig/ml undiluted) were
added and ELISA performed. The 150 K protein was able to inhibit the
antibodies to the crude extract in the representative serum. No inhibi-
tion was observed with NC!. The amounts of 150 K protein and crude
extract required for 50% inhibition were 2 p/ml and 12 zg/ml,
respectively.
GBM and the 150 K protein were electrophoresed on SDS
polyacrylamide slab gel. The proteins were transferred electro-
phoretically to nitrocellulose sheets and immunostained with a
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Fig. 4. Speqficity of the antibodies to 6 M guanidine-HC1 extract of
bovine GBM in an immunoblotting experiment. Crude guanidine extract
and the purified 150 K proteins were electrophoresed on a 4 to 15%
polyacrylamide slab gel. The separated proteins were transferred
electrophoretically to nitrocellulose papers and immunostained with
rabbit anti-15O K serum (reference serum), a serum positive for anti-ISO
K antibodies (serum I), a serum negative for those antibodies (serum 2)
and a mixture of serum 1 and 150 K protein. Lanes I and 2 represent the
staining of the crude guanidine extract (CGE) and 150 K protein,
respectively, with the reference serum; lanes 3 and 4, the staining of
CGE and 150 K with serum I; lanes Sand 6, the staining of CGE and 150
K with serum 2, while lanes 7 and 8 represent the staining of CGE and
150 K protein with the mixture of serum 1 and 150 K protein.
positive serum for antibodies to the 150 K protein (serum 1) and
one negative for those antibodies (serum 2). In addition, for
control, transblotted proteins were immunostained with the
reference serum (rabbit anti-iSO K serum). Furthermore, one
set was incubated with serum 1 already mixed with the 150 K
protein. It was observed that the staining pattern for the
reference serum and serum 1 was similar. Both stained the pure
150 K band and the corresponding band in the crude guanidine
extract. No staining was observed with serum 2 or with the
mixture of serum 1 and the 150 K protein (Fig. 4). Several bands
in the crude extract were stained both by the reference serum
and serum 1. These bands probably represent the fragments of
the 150 K protein containing the antigenic epitopes that react
with anti-iSO K antibodies present in rabbit anti-150 K antise-
rum as well as in the patient's serum. This is supported by the
fact that no staining was observed with the normal serum and
that the staining of all the bands by serum 1 was inhibited by 150
K protein.
Identification of the 150 K protein as entactin
Amino acid composition of the 150 K protein is summarized
in Table 1. It is comparable to that of entactin purified by Carlin
et al [25] and of nidogen purified by Timpi et al [26, 351 (Table
1). Furthermore, this 150 K protein was radiolabeled with 1251
and precipitated with serial dilutions of two different antibodies
(anti-nidogen and anti-150 K antibodies) in a RIA experiment.
The amount of the radiolabeled protein precipitated by the two
antibodies was similar (Fig. 5). In addition, the reactivity of the
150 K protein to four different antibodies (rabbit anti-iSO K
polyclonal, rabbit anti-entactin polyclonal, and mouse anti-
entactin monoclonal a and a' antibodies) in a sandwich ELISA
was comparable (Fig. 6). The latter three antibodies were raised
against entactin which was isolated from bovine GBM and
sequenced for amino acid on a thrombin peptide [33]. The
Table 1. Amino acid composition of the 150 K protein compared to
the published amino acid composition of nidogen/entactin
Amino Nidogen 150 Entactin
acida 150 K [26, 35] [25]
Asp 100 99 113
Thr 64 66 64
Ser 98 85 84
Glu 118 113 123
Pro 72 67 76
Gly 104 105 111
Ala 73 60 67
Cys 23 32 24
Val 43 57 44
Met 9 5 10
LIe 28 37 27
Leu 74 66 69
Tyr 34 36 34
Phe 46 36 34
His 36 33 28
Lys 20 31 34
Arg 58 55 51
Trp — 17 7
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Fig. 5. Precipitation of the 150 K protein by two different antibodies in
a radioimmunoassay. The 150 K protein was radiolabeled with 1251 and
mixed with serial dilutions of two different antibodies (anti-nidogen, 0,
and anti-ISO K, •, antibodies) and RIA performed using double
antibody technique. The amount of precipitation of the 150 K protein by
the two antibodies was comparable.
amino acid sequence of bovine entactin was similar to those of
mouse nidogen [27] and entactin [28]. Furthermore, bovine
entactin was able to inhibit antibodies to 150 K protein in a
patient's serum (Fig. 7). Moreover, analysis of sera from
different patients for anti-iSO K and anti-entactin antibodies, as
described below, yielded similar results. All these results, taken
together, suggest that the 150 K protein which we isolated from
the crude 6 54 guanidine-HCI extract of bovine GBM is entactin!
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Hg. 6. Activity of the 150 K protein to different antibodies on a
sandwich ELISA. The isolated 150 K protein was coated to microtiter
plates and ELISA performed using four different first antibodies: (0)
rabbit anti-iSO K; (0) rabbit anti-entactin polyclonal, (I) mouse
anti-entactin a and () a' monoclonal antibodies. All antibodies reacted
well with the 150 K protein.
0.0
Dilution of antigens
Fig. 7. Inhibition of anti-150 K antibodies by nidogen. Serial dilutions
of bovine entactin (0) and Goodpasture antigen (•) were mixed with a
fixed dilution of a representative serum, transferred to a microtiter plate
coated with the 150 K protein and ELISA performed. Bovine entactin
was able to inhibit anti-l50 K antibodies in the representative serum,
while no inhibition was observed with the Goodpasture antigen.
absorbance depended on concentration, it indicated a specific
binding of immunoglobulins to the coated antigen. Analysis for
the presence of anti-entactin antibodies, by this ELISA, in the
sera from eighty-nine patients with renal disease who already
had shown IgG/IgM/IgA antibodies to the crude guanidine
extract of GBM [24] showed that thirty-two patients had 1gM,
lgG or both antibodies to entactin. The majority of patients (22
patients) had 1gM; seven had IgG while three had both IgG and
1gM antibodies to entactin. None had IgA anti-entactin antibod-
ies. None of the forty-five normal sera had positive reaction for
anti-entactin antibodies, while only two of the 18 Goodpasture
sera analyzed showed positive results (Fig. 9). Furthermore,
those patients who showed IgG anti-entactin antibodies were
analyzed for IgG subclasses. Interestingly all the 10 patients
had IgG4 subclass, and three patients additionally had IgG2
subclass of anti-entactin antibodies. No sera contained IgG3 or
IgG4 anti-entactin antibodies (data not shown).
Role of anti-Gal al-3Gal antibodies
1/10 Glycoproteins from bovine origin may contain the carbohy-
drate epitope, Gal al-3 Gal. Since anti-Gal al-3 Gal is the most
common natural antibody in man [36] it was important to rule
out that the antibodies that we measured in patients' sera were
anti-entactin antibodies and not anti-Gal al-3 Gal antibodies.
Hence, we randomly selected 40 different sera, including sera
from the patients as well as normal sera, and simultaneously
tested for the presence of the two antibodies. It was observed
that most of these sera, including normal sera had high titers of
the antibodies to Gal al-3Gal, while only a few had high titers
of anti-entactin antibodies (Fig. 10). There was no correlation
between the presence of anti-entactin and anti-Gal al-3Gal
antibodies (r +0,185, P > 0.05). Furthermore, in a study of
ELISA inhibition, two sera, one positive for both anti-entactin
and anti-Gal al-3Gal antibodies and the other positive only for
anti-Gal al-3Gal antibodies were mixed serially with different
dilutions of Gal al-3Gal and entactin, transferred next day to
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1/1000 1/500 1/250 Fig. 8. Sensitivity of ELISA for detection of anti-entactin antibodies.
A microtiter plate was coated with entactin and serial dilutions of a
representative serum (0, serum that had previously shown antibodies
to entactin) and a normal serum (•) were added and ELISA performed.
The representative serum had to be diluted 1280 times before its optical
density became equal to that of the normal serum.
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Detection of anti-entactin antibodies in patients' sera by
ELISA
Entactin was able to coat well to the microtiter plates.
Moreover, the assay was quite sensitive as determined by the
dilution curve of a representative serum where the serum could
be diluted 1280 times before its absorbance became equal to
that of the normal serum (Fig. 8). Additionally, since the
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Fig. 9. Anti-entactin antibodies in patients
with glomerulonephritis who have high igGi
IgMilgA antibodies to the crude guanidine
extract of GBM. Eighty-nine sera from
patients with different types of
glomerulonephritis, 18 sera from patients with
Goodpasture's syndrome and 45 normal sera
were analyzed for the presence of anti-
entactin antibodies by ELISA. Thirty-two
patients with various types of
glomerulonephritides possessed 1gM or IgG or
both antibodies to entactin. Only two patients
with GP syndrome had anti-entactin
antibodies while none of the normal sera
showed anti-entactin antibodies.
microtiter plates coated with Gal al-3Gal-HSA and entactin
and ELISA performed. It was observed that neither Gal al-
3Gal was able to block anti-entactin antibodies nor entactin was
able to block anti-Gal al-3Gal antibodies (data not shown).
Discussion
Apart from classical Goodpasture's antigen the occurrence of
other GBM antigens in the pathogenesis of anti-GBM nephritis
is by and large unknown. Our recent observations that many
patients with glomerulonephritis show a consistent presence of
antibodies to the crude guanidine extract of GBM [241 prompted
us to purify proteins from the guanidine extract of GBM. In the
present study we have isolated a 150 K protein from 6 M
guanidine-HCI extract of bovine GBM. Amino acid analysis of
this protein showed similarity to entactin/nidogen (Table 1),
which was further suggested by a RIA experiment using two
different antibodies (Fig. 5). Furthermore, entactin was inde-
pendently isolated from bovine GBM and sequenced for amino
acids [33]. Antibodies raised to the bovine entactin reacted well
with the 150 K protein in ELISA experiments (Fig. 6). More-
over, bovine entactin was able to inhibit antibodies to the 150 K
protein in a patient's serum (Fig, 7). Additionally all the sera
analyzed for anti-l50 K antibodies showed similar reactivity to
bovine entactin. All these observations imply that the 150 K
protein isolated from guanidine extract of bovine GBM is
entactin/nidogen.
Furthermore, on coating entactin to microtiter plates and
performing ELISA we have shown that many sera that had
previously reacted with the crude extract [24] have IgG/IgM
antibodies to entactin. No serum had IgA anti-entactin antibod-
ies. Interestingly, none of the normal sera tested showed any
reaction to entactin (Fig. 9). Moreover, entactin was able to
block the activity of antibodies to the crude guanidine extract in
a representative serum by ELISA inhibition (Fig. 3) and immu-
noblotting experiments (Fig. 4), thereby suggesting that the
antibodies to the crude 6 M guanidine-HCI extract of GBM in
many sera were actually directed against entactin.
Since we isolated entactin from bovine kidneys, there was a
distinct possibility that it might contain Gal al-3 Gal, a carbo-
hydrate epitope present in many mammalian species but lacking
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in humans, although all human beings possess natural IgG
anti-Gal al-3 Gal antibodies in their blood [361. Therefore, it
was necessary for us to examine whether the antibodies in the
sera of various patients positive for entactin were actually
directed against entactin and not, as in case of laminin in
Chaga's disease [37, 38] and American cutaneous Leishmania-
sis [38, 39] directed against Gal al-3 Gal. It could be observed
that both anti-entactin positive and negative sera as well as
normal sera showed antibodies to Gal al-3 Gal (Fig. 10). There
was no correlation between the presence of anti-entactin and
anti-Gal al-3 Gal antibodies in these sera. Furthermore, Gal
al-3 Gal was not able to block the antibodies to entactin and
entactin was not able to block anti-Gal al-3 Gal antibodies in
inhibition ELISA. These observations collectively imply that
anti-entactin antibodies that we analyzed are not the same
antibodies as those directed to the Gal al-3 Gal epitope. In
other words anti-entactin and anti-Gal al-3 Gal antibodies are
two different antibodies.
For the present study we randomly selected sera from
various patients with glomerulonephritis who had previously
shown high IgGtIgM/IgA antibody titers against crude guani-
dine extract of GBM [24]. These patients comprised both
primary glomerulonephritides and secondary glomerulonephrit-
ides, mainly to systemic vasculitides and systemic connective
tissue diseases with varying degrees of renal involvement.
About one third of these patients showed IgG/IgM antibodies to
entactin. Interestingly, only two of the 18 Goodpasture sera
showed antibodies to entactin. One of them had systemic
vasculitis and the other had an atypical presentation with
positive tests for anti-nuclear antibodies. None of the sera
contained IgA anti-entactin antibodies. Moreover, none of the
normal sera possessed anti-entactin antibodies. All these results
indicate that there is a distinct group of patients with glomeru-
lonephritis who show autoantibodies to entactin. Most of these
patients are generally classified as having immune complex
disease on the basis of appearance of granular pattern of
antibody deposition along the GBM by immunofluorescence
microscopy. Studies in experimental models of autoimmune
nephritis such as mercuric chloride-induced nephritis in Brown
Norway rats [22, 40] and more recently, in murine GvH disease
model which is akin to the clinical syndrome of SLE [41, 42],
have shown that to begin with the antibodies are deposited
linearly along the GBM but gradually the pattern changes to
granular type, probably because of the reorganization of the
antigen antibody complexes. Such phenomenon possibly also
exists in human beings but will require early as well as sequen-
tial renal biopsies for its elucidation. Nevertheless the observa-
tions in experimental models indicate that there is no clear cut
demarcation between the immune complex and the anti-GBM
glomerulonephritis classified on the basis of granular or linear
pattern on immunofluorescence microscopy [43]. Many of the
immune complex glomerulonephntis thus classified may actu-
ally be mediated by anti-GBM antibodies directed to certain
autoantigens in the basement membrane, as is probably the case
with those patients who have circulating antibodies to entactin.
Our demonstration of anti-entactin antibodies in such patients is
a step forward in this direction, although further studies are
required to prove their precise role in the pathogenesis of
glomerulonephritis. Moreover, it will be necessary to find out
the pattern in which the anti-entactin antibodies are present in
various patients with glomerulonephritis and their possible
correlation with the clinical features, severity and the progres-
sion of the disease. Preliminary results from a study involving
analysis of anti-entactin antibodies in 305 consecutive biopsy-
proven patients with various glomerular diseases indicate that
anti-entactin antibodies are present with a definite pattern in
270 Saxena ci' a!: Entactin in anti-GBM nephritis
2.5
a
2.0
15' • •
C.,C a
Cg 1.0.
••
. • Fig. 10. Correlation between the presence of• anti-entactin and anti-Gal al-3 Ga!
• •D sa •• antibodies. Forty different sera including sera
a0.5' • a • • • from patients with different types ofglomerulonephritis and normal sera were
• randomly selected for simultaneous estimationa a
•. ofanti-entactin (0) and anti-Gal al-3Gal (•)antibodies. Most of these sera had high titres
of anti-Gal al-3Gal antibodies, while only aa
0.0 • • • • ! riD90DDp..v,ICiID few of them had high titers of anti-entactinantibodies. There was no correlation between0 4 8 12 16 20 24 28 32 36 40 the presence of the two antibodies in these
Sera sera (r = +0,185; P > 0.05).
Saxena et a!: Entactin in anti-GBM nephritis 271
these patients (Saxena et a!, manuscript in preparation). They
are present both in primary as well as in secondary glomerulo-
nephritides. Among primary glomerulonephritides, anti-entac-
tin antibodies are mainly distributed among young patients (18
to 30 years) with mesangioproliferative glomerulonephritis as-
sociated with nephrotic or sub-nephrotic grade proteinuria. On
the other hand, among secondary glomerulonephritides these
antibodies are mainly distributed among relatively older pa-
tients (51 to 60 years) with SLE or SLE-like collagen vascular
diseases. They are absent in non-inflammatory conditions like
amyloidosis, nephrosclerosis, diabetic nephropathy and mini-
mal change disease (Saxena et a!, manuscript in preparation).
Although attempts to stain normal human kidneys by anti-
entactin positive sera have been unsuccessful so far, a highly
significant correlation has been observed between the presence
of circulating anti-entactin antibodies and the deposition of
corresponding class of immunoglobulin along the GBM on
direct immunofluorescence. Moreover, absence of immune
deposits along GBM on direct immunofluorescence is associ-
ated with negative results for anti-entactin antibodies by ELISA
(Saxena et al, manuscript in preparation). Furthermore, a high
prevalence of complement fixing IgG1 anti-entactin antibodies
also supports the possible pathogenic role of anti-entactin
antibodies in certain forms of glomerulonephritides.
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